Three Peaks Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Three Peaks Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$3.54M	Sell	4,741 -111	-2%	-$83.2K	1.18%	35
2021 Q2	$3.13M	Hold	4,852	–	–	0.96%	57
2021 Q1	$2.77M	Sell	4,852 -1,039	-18%	-$615K	0.87%	49
2020 Q4	$3.43M	Sell	5,891 -876	-13%	-$499K	1.1%	32
2020 Q3	$3.49M	Sell	6,767 -620	-8%	-$314K	1.23%	27
2020 Q2	$3.33M	Sell	7,387 -7,292	-50%	-$3.22M	1.23%	31
2020 Q1	$5.15M	Sell	14,679 -994	-6%	-$365K	2.06%	4
2019 Q4	$5.8M	Sell	15,673 -1,154	-7%	-$407K	1.53%	16
2019 Q3	$5.6M	Sell	16,827 -260	-2%	-$84.8K	1.61%	12
2019 Q2	$5.34M	Buy	17,087 +4,074	+31%	+$1.22M	1.55%	22
2019 Q1	$3.98M	Sell	13,013 -82	-0.6%	-$22.1K	1.17%	35
2018 Q4	$3.04M	Sell	13,095 -2,888	-18%	-$775K	0.95%	34
2018 Q3	$5M	Sell	15,983 -1,958	-11%	-$608K	1.03%	25
2018 Q2	$5.18M	Buy	17,941 +14,450	+414%	+$3.99M	1.04%	25
2018 Q1	$873K	Buy	+3,491	New	+$889K	0.15%	98
2014 Q1	–	Sell	-27,026	Closed	-$3.34M	–	72
2013 Q4	$3.34M	Buy	+27,026	New	+$3.29M	1.68%	24

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Three Peaks Capital Management's BIO Position: Q3 2021 in Review

Three Peaks Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.3% in Q3 2021, selling an estimated $83.2K and leaving 4,741 shares worth $3.54M. The position accounts for 1.18% of the portfolio, ranked #35.

Three Peaks Capital Management first reported a position in BIO in Q4 2013 and has held it in 16 quarters since. The position peaked at $5.8M in Q4 2019. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

Three Peaks Capital Management held 4,741 shares of Bio-Rad Laboratories Class A worth $3.54M as of Q3 2021.
Three Peaks Capital Management sold 111 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $83.2K.
Bio-Rad Laboratories Class A made up 1.18% of Three Peaks Capital Management's portfolio in Q3 2021, its #35 holding.
Three Peaks Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2013 and has held it in 16 quarters since.
Three Peaks Capital Management's Bio-Rad Laboratories Class A position peaked at $5.8M in Q4 2019.
507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Three Peaks Capital Management's 13F filing for Q3 2021, filed 12 Oct 2021.